NERV vs. RMTI, VTGN, HOOK, RZLT, DNTH, CLSD, MEIP, IPA, SLS, and VTVT
Should you be buying Minerva Neurosciences stock or one of its competitors? The main competitors of Minerva Neurosciences include Rockwell Medical (RMTI), Vistagen Therapeutics (VTGN), Hookipa Pharma (HOOK), Rezolute (RZLT), Dianthus Therapeutics (DNTH), Clearside Biomedical (CLSD), MEI Pharma (MEIP), ImmunoPrecise Antibodies (IPA), SELLAS Life Sciences Group (SLS), and vTv Therapeutics (VTVT). These companies are all part of the "pharmaceutical preparations" industry.
Rockwell Medical (NASDAQ:RMTI) and Minerva Neurosciences (NASDAQ:NERV) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their community ranking, dividends, profitability, media sentiment, institutional ownership, risk, analyst recommendations, earnings and valuation.
Minerva Neurosciences has a net margin of 0.00% compared to Minerva Neurosciences' net margin of -15.32%. Rockwell Medical's return on equity of 0.00% beat Minerva Neurosciences' return on equity.
22.1% of Rockwell Medical shares are owned by institutional investors. Comparatively, 55.1% of Minerva Neurosciences shares are owned by institutional investors. 2.2% of Rockwell Medical shares are owned by company insiders. Comparatively, 6.4% of Minerva Neurosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Rockwell Medical has higher revenue and earnings than Minerva Neurosciences. Rockwell Medical is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks.
Rockwell Medical currently has a consensus price target of $11.00, indicating a potential upside of 439.22%. Minerva Neurosciences has a consensus price target of $11.00, indicating a potential upside of 62.96%. Given Minerva Neurosciences' stronger consensus rating and higher probable upside, research analysts plainly believe Rockwell Medical is more favorable than Minerva Neurosciences.
Minerva Neurosciences received 50 more outperform votes than Rockwell Medical when rated by MarketBeat users. Likewise, 62.08% of users gave Minerva Neurosciences an outperform vote while only 57.34% of users gave Rockwell Medical an outperform vote.
In the previous week, Rockwell Medical had 5 more articles in the media than Minerva Neurosciences. MarketBeat recorded 7 mentions for Rockwell Medical and 2 mentions for Minerva Neurosciences. Minerva Neurosciences' average media sentiment score of 0.69 beat Rockwell Medical's score of 0.63 indicating that Rockwell Medical is being referred to more favorably in the media.
Rockwell Medical has a beta of 1.4, meaning that its share price is 40% more volatile than the S&P 500. Comparatively, Minerva Neurosciences has a beta of 0.25, meaning that its share price is 75% less volatile than the S&P 500.
Summary
Rockwell Medical beats Minerva Neurosciences on 10 of the 18 factors compared between the two stocks.
Get Minerva Neurosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for NERV and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NERV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Minerva Neurosciences Competitors List
Related Companies and Tools
